Envisagenics fetches Series A

Envisagenics, a developer of novel RNA splicing therapeutics, has secured an undisclosed amount of Series A funding.

Envisagenics, a developer of novel RNA splicing therapeutics, has secured an undisclosed amount of Series A funding. Red Cell Partners led the round with participation from other backers that included Microsoft’s M12, Madrona Venture Group, Third Kind Venture Capital, Dynamk Capital, and Empire State Development’s venture capital arm, New York Ventures.

Source: Press Release